Physician profile
Vasanthi Srinivas
NPI 1548287485
$3,953.72
in general payments reported to CMS, 2019-2025
28 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $370 · 2021: $489 · 2022: $197 · 2023: $1,789 · 2024: $378 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688 · Travel and Lodging: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,687.76 |
| Travel and Lodging | $712.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,090.42 | 2023 | Altis |
| Abbvie INC. | $733.21 | 2019-2023 | Lo Loestrin Fe, Liletta, Orilissa |
| Hologic Sales and Service, LLC | $209.98 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $199.03 | 2019-2024 | |
| Sage Therapeutics, LLC | $194.95 | 2020-2025 | Zurzuvae |
| Astellas Pharma US INC | $179.94 | 2023-2025 | Veozah |
| Agile Therapeutics, INC. | $177.12 | 2021-2024 | Twirla |
| Sumitomo Pharma America, INC. | $175.57 | 2023-2025 | Myfembree, Gemtesa |
| Merck Sharp & Dohme LLC | $143.09 | 2019-2021 | |
| Dexcom, INC. | $124.06 | 2023 | Dexcom G7 Gss (161) |
| Shield Therapeutics INC | $104.93 | 2023-2025 | Accrufer |
| Myovant Sciences INC. | $90.18 | 2021-2022 | |
| Organon LLC | $73.03 | 2021-2025 | Nexplanon |
| Therapeuticsmd, INC. | $60.73 | 2020 | |
| Haemonetics Corporation | $54.12 | 2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $47.37 | 2021-2023 | Phexxi |
| Daiichi Sankyo INC. | $45.40 | 2019-2023 | Injectafer |
| Allergan, INC. | $36.12 | 2019-2020 | |
| Coopersurgical, INC. | $33.50 | 2025 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $33.00 | 2024 | |
| Lupin INC. | $27.04 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.34 | 2019 | |
| Medtronic USA, INC. | $22.02 | 2019 | |
| Smith+Nephew, INC. | $17.98 | 2023 | Grafix Pl |
| Meditrina | $17.56 | 2025 | |
| Roche Diagnostics Corporation | $14.80 | 2019 | |
| Avion Pharmaceuticals | $13.29 | 2019 | |
| Axonics, INC. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasanthi Srinivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.